Powered by

AI Therapeutics Announces that a Common LAM-002 Mechanism in Cancer and Neurodegenerative Diseases Shows Antitumor Activity in the Clinic and Hope for ALS; Company Receives FDA Guidance for Pivotal Trial Design in Follicular Lymphoma to Support Accelerate

Jan 16, 2020 - Business Wire

AI Therapeutics is a clinical-stage biopharmaceutical company that has created an artificial intelligence-driven drug development platform for matching drugs to new indications. The company has made significant recent progress with its four clinical assets and proprietary Guardian Angel(TM) algorithm.

LAM-002 is a first-in-class, PIKfyve kinase inhibitor that activates transcription factor EB (TFEB), the master regulator of lysosomal biogenesis.1 TFEB activation clears toxic aggregates tha...